Radiotherapy and Oncology最新文献

{"title":"The significance of dose heterogeneity on the anti-tumor response of minibeam radiation therapy","authors":"Sarah Potiron ,&nbsp;Lorea Iturri ,&nbsp;Marjorie Juchaux ,&nbsp;Julie Espenon ,&nbsp;Cristèle Gilbert ,&nbsp;Josie McGarrigle ,&nbsp;Ramon Ortiz Catalan ,&nbsp;Alfredo Fernandez-Rodriguez ,&nbsp;Catherine Sebrié ,&nbsp;Laurène Jourdain ,&nbsp;Ludovic De Marzi ,&nbsp;Gilles Créhange ,&nbsp;Yolanda Prezado","doi":"10.1016/j.radonc.2024.110577","DOIUrl":"10.1016/j.radonc.2024.110577","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Proton Minibeam Radiation Therapy (pMBRT) is an unconventional radiation technique based on a strong modulation of the dose deposition. Due to its specific pattern, pMBRT involves several dosimetry (peak and valley doses, peak-to-valley dose ratio (PVDR)) and geometrical parameters (beam width, spacing) that can influence the biological response. This study aims at contributing to the efforts to deepen the comprehension of how the various parameters relate to central biological mechanisms, particularly anti-tumor immunity, and how these correlations affect treatment outcomes with the goal to fully unleash the potential of pMBRT. We also evaluated the effects of X-ray MBRT to further elucidate the influence of peak dose and dose heterogeneity.</div></div><div><h3>Methods and Materials</h3><div>An orthotopic rat model of glioblastoma underwent several pMBRT configurations. The impact of different dosimetric parameters on survival and on the modulation of crucial mechanisms for pMBRT, such as immune response, was investigated. The latter was assessed by immunohistochemistry and flow cytometry at 7 days post-irradiation.</div></div><div><h3>Results</h3><div>Survival was improved across the various pMBRT regimens via maintaining a minimum valley dose as well as a higher dose heterogeneity, which is driven by peak dose. While the mean dose did not impact immune infiltration, a higher PVDR promoted a less immunosuppressive microenvironment.</div></div><div><h3>Conclusions</h3><div>Our results suggest that both tumor eradication, and immune infiltration are associated with higher dose heterogeneity. Higher dose heterogeneity was achieved by optimizing the peak dose, as well as maintaining a minimum valley dose. These parameters contributed to direct tumor eradication as well as reduction of immunosuppression, which is a departure from the more immunosuppressive tumor environment found in conventional proton therapy that delivers uniform dose distributions.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110577"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overestimation of contralateral hilar lymph node metastasis in non-metastatic non-small cell lung cancer and its predictive model: HAM","authors":"Zan Hou ,&nbsp;Xiaoping Lin ,&nbsp;Baiqiang Dong ,&nbsp;Zaishan Lin ,&nbsp;Yuan Zhang ,&nbsp;Xu Liu ,&nbsp;Chenfei Wu ,&nbsp;Qingqing Xu ,&nbsp;Ying Wang ,&nbsp;Keying Chen ,&nbsp;Qiwen Li ,&nbsp;Ming Chen","doi":"10.1016/j.radonc.2024.110575","DOIUrl":"10.1016/j.radonc.2024.110575","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Metastasis of non-metastatic non-small cell lung cancer (NMNSCLC) to contralateral hilar lymph nodes (CHLN) eliminates the opportunity for radical therapy. This study aims to analyze whether CHLN metastasis in NMNSCLC is commonly overestimated in clinical practice and to establish a predictive model for enhanced precision.</div></div><div><h3>Methods and materials</h3><div>We conducted a retrospective analysis of 834 pathologically confirmed NMNSCLC patients. Monitoring of treatment responses and regular ≥ 1 year CT follow-up was used to determine the nature of CHLN. Lasso regression was used to select predictive factors, and a multivariate binary logistic regression model (HAM) was constructed. Internal validation was performed using ten-fold cross-validation.</div></div><div><h3>Results</h3><div>The CHLN metastasis rate was 4.4% among the NMNSCLC patients. The positive predictive value (PPV) and sensitivity for PET-CT diagnosis were 36.8% and 67.5%, while for CT they are 44.8% and 70.2%, respectively. The five optimal predictive factors (emphysema or bullae, central-type lung cancer, short diameter of CHLN, calcification and SUVmax) were used to develop the HAM model. The Area under curve (AUC) values for PET-CT, CT, and HAM model were 0.81, 0.83, and 0.96, respectively. The F1 scores for PET-CT and CT were 0.48 and 0.55, respectively, while the maximum F1 score of our model was 0.73, with corresponding PPV and sensitivity of 66.7%, and 81.1%, respectively.</div></div><div><h3>Conclusions</h3><div>CHLN metastasis is rare in NMNSCLC patients. PET-CT diagnosis significantly overestimates CHLN metastasis and the HAM model improves clinical decision-making in this study. Prospective studies are needed to confirm these conclusions.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110575"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of upright patient positioning reproducibility in image-guided proton therapy for head and neck cancers","authors":"J. Feldman ,&nbsp;A. Pryanichnikov ,&nbsp;D. Shwartz ,&nbsp;Y. Hillman ,&nbsp;M. Wygoda ,&nbsp;P. Blumenfeld ,&nbsp;M. Marash ,&nbsp;A. Popovtzer","doi":"10.1016/j.radonc.2024.110572","DOIUrl":"10.1016/j.radonc.2024.110572","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the patient’s positioning reproducibility during upright treatment with image-guided adaptive proton therapy (IGAPT) for head and neck cancers.</div></div><div><h3>Materials and methods</h3><div>10 head and neck (H&amp;N) patients were treated with gantry-less IGAPT, which includes daily 3D computed tomography (CT) and two 2D kilovoltage radiographs before treatment and weekly 3DCT immediately after irradiation. All procedures were performed in the carbon chair on the 6 degrees of freedom robotic positioner.</div></div><div><h3>Results</h3><div>Prior to treatment we registered shifts in patient positioning using 3D/3D registration at the imaging isocenter: X  = -0.1 ± 3.9 (mean ± standard deviation) mm, Y = −3.7 ± 3.5 mm, Z = 0.5 ± 6.2 mm. The corresponding vector was applied to the robotic positioner to compensate for the registered shifts, after which the patients were moved to the treatment isocenter and the following shifts were obtained there using 2D/3D registration: X  = -0.31 ± 1.37 mm, Y = −0.02 ± 1.33 mm, Z = 0.59 ± 1.55 mm. Finally, the weekly follow-up 3D/3D registration showed X  = -0.2 ± 1.2 mm, Y = −0.0 ± 1.4 mm, Z = 2.3 ± 2.0 mm.</div></div><div><h3>Conclusions</h3><div>A novel image-guided gantry-less PT facility showed reliable results in terms of patient positioning for H&amp;N cases during clinical trials. This fact confirmed the suitability of using gantry-less PT for H&amp;N treatment. A small, systematic shift in the vertical direction was detected in the follow-up 3D/3D registration. The effect of this shift will be investigated in further studies with pre/post treatment 2D/3D registration. The next phase of the clinical trial of this facility is dedicated to the thorax region.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110572"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy?","authors":"Ruichen Li ,&nbsp;Yang Zhao ,&nbsp;Kangting Wu,&nbsp;Huiqing Li,&nbsp;Xinru Lin,&nbsp;Liting Zhu,&nbsp;Yi Zhu,&nbsp;Xiaoshen Wang","doi":"10.1016/j.radonc.2024.110578","DOIUrl":"10.1016/j.radonc.2024.110578","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify whether p16 status or response to induction chemotherapy (IC) predicts the radiotherapy (RT) response and survival outcomes in Chinese oropharyngeal squamous cell carcinoma (OPSCC).</div></div><div><h3>Methods</h3><div>A total of 211 patients, including 128 p16-positive and 83 p16-negative were analyzed. All patients underwent IC followed by definitive RT or concurrent chemoradiotherapy (CCRT). Propensity score matching (PSM) was used to eliminate the baseline variations.</div></div><div><h3>Results</h3><div>Age, sex, smoking history, alcohol history, and primary site were unbalanced between different p16 status subgroups. Before PSM, the objective response rates to IC between p16-positive and p16-negative groups were 80.5 % and 85.5 % (p = 0.344). After RT, the complete response (CR) rates were 73.4 % and 66.3 %, respectively (p = 0.264). IC-sensitive (IC-s) subgroups had a higher percentage of RT-CR rate than the IC-resistant (IC-r) subgroups in both p16-positive and p16-negative patients. IC-s showed significant improvement in cancer-specific survival (CSS) (92.9 % vs. 53.6 %, p &lt; 0.0001), progression-free survival (PFS) (p &lt; 0.0001), locoregional relapse-free survival (LRFS) (p &lt; 0.0001) and distant metastasis-free survival (DMFS) (p = 0.025). After PSM, the CR rates among different p16 groups remained comparable following RT (71.2 % vs. 65.8 %, p = 0.476). Before or after PSM, CSS, PFS, LRFS, and DMFS were similar between different p16 status either in IC-s or IC-r subgroups (p &gt; 0.05). IC-r was independently associated with shorter PFS (HR = 2.661, p = 0.002) and LRFS (HR = 2.876, p = 0.002; HR = 2.78, p = 0.018).</div></div><div><h3>Conclusions</h3><div>Response to IC is an important predictor of prognosis in Chinese OPSCC treated with definitive RT. Poor response to IC is associated with unsatisfactory outcomes either in p16-positive or p16-negative OPSCC.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110578"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost","authors":"Mette S. Thomsen ,&nbsp;Jan Alsner ,&nbsp;Christina M. Lutz ,&nbsp;Martin Berg ,&nbsp;Ingelise Jensen ,&nbsp;Ebbe L. Lorenzen ,&nbsp;Hanne M. Nielsen ,&nbsp;Erik H. Jakobsen ,&nbsp;Lars Stenbygaard ,&nbsp;Mette H. Nielsen ,&nbsp;Maj-Britt Jensen ,&nbsp;Jens Overgaard ,&nbsp;Birgitte V. Offersen ,&nbsp;on behalf of the DBCG RT Committee","doi":"10.1016/j.radonc.2024.110574","DOIUrl":"10.1016/j.radonc.2024.110574","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the association between irradiated breast volume and grade 2–3 breast induration three years after radiotherapy in the phase III Danish Breast Cancer Group HYPO trial randomizing patients ≥ 41 years to whole breast irradiation (WBI) with 40 Gy/15fr versus 50 Gy/25fr.</div></div><div><h3>Methods</h3><div>Treatment plans were available for all Danish patients. Associations between frequency of induration and irradiated volume, age, smoking status, and boost were assessed by logistic regression. A sequential boost was given to patients &lt; 50 years or in case of a narrow (&lt;2 mm) resection margin.</div></div><div><h3>Results</h3><div>RT plans from 1,333 patients were analyzed with 178 (13 %) having grade 2–3 induration. 1135 patients had only WBI. For this group, induration was correlated with irradiated breast volume for patients ≥ 65 years (n = 343, 10 %/22 % for small/large irradiated volumes, p = 0.005) but not for patients aged 50–64 years (n = 792, 11 % for both small and large volumes, p = 0.82). Smoking doubled the frequency irrespective of irradiated volume and age. All patients &lt; 50 years (n = 156) had a boost. A volume effect was found for this group (5 %/21 % induration for small/large volume, p = 0.002). 42 patients ≥ 50 years had a boost and 14 (33 %) had grade 2–3 induration, however, with a p-value &gt; 0.05 due to the few numbers of patients.</div></div><div><h3>Conclusion</h3><div>A relationship between irradiated breast volume and 3-year frequency of breast induration was found for patients ≥ 65 years, whilst not for patients aged 50–64 years. Smoking doubled the risk of induration irrespective of volume and age. A dose-induration relationship was seen for boost patients &lt; 50 years.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110574"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transit-guided radiation therapy: a novel patient monitoring approach","authors":"Artur Latorre-Musoll ,&nbsp;Gabriela Oses ,&nbsp;Gabriela Antelo ,&nbsp;Sergi Serrano-Rueda ,&nbsp;Meritxell Mollà ,&nbsp;Josep Sempau ,&nbsp;Núria Jornet","doi":"10.1016/j.radonc.2024.110580","DOIUrl":"10.1016/j.radonc.2024.110580","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Transit-Guided Radiation Therapy (TGRT) is a novel technique that uses the transit portal images (TPIs) acquired with Electronic Portal Image Devices (EPID) to quantify patient position errors during the treatment. It has been validated using anthropomorphic phantoms but a validation in a clinical setting was lacking. A pilot clinical study is presented to confirm our previous results.</div></div><div><h3>Materials and methods</h3><div>A prospective study was conducted between June and December 2022 with patients who received whole-brain or breast radiotherapy treatments. The selected treatments were composed of radiation fields using skin-flash, where the body contour projected a sharp edge on the EPID which has been used as a surrogate of the true patient position. Daily imaging procedures were applied as scheduled before running the one- and two-parameter model (1PM and 2PM) of the TGRT formalism on the acquired TPIs to independently estimate the patient position errors.</div></div><div><h3>Results</h3><div>43 patients and 1015 TPIs have been assessed. The 2PM showed a better correlation with the true position errors (<em>R</em>² = 0.76 vs. 0.73), a lower detection threshold (0.77 mm vs. 1.24 mm), and a lower overcorrection risk above the detection threshold (7.0 % vs. 11.1 %) than the 1PM. Overall, the 2PM would have significantly reduced the true position errors by a factor of 0.58 (0.49 – 1.27) (<em>p</em> &lt; 0.0001).</div></div><div><h3>Conclusion</h3><div>The TGRT technique has confirmed the ability to reduce the position errors in a clinical setting, demonstrating the potential to enhance the patient position monitoring without increasing treatment time or patient dose.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110580"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142446946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A model-based risk-minimizing proton treatment planning concept for brain injury prevention in low-grade glioma patients","authors":"H. Sallem ,&nbsp;S. Harrabi ,&nbsp;E. Traneus ,&nbsp;K. Herfarth ,&nbsp;J. Debus ,&nbsp;J. Bauer","doi":"10.1016/j.radonc.2024.110579","DOIUrl":"10.1016/j.radonc.2024.110579","url":null,"abstract":"<div><h3>Purpose</h3><div>Late-occurring contrast-enhancing brain lesions (CEBLs) have been observed on MRI follow-up in low-grade glioma (LGG) patients post-proton therapy. Predictive risk-models for this endpoint identified a dose-averaged linear energy transfer (LET_d)-dependent proton relative biological effectiveness (RBE) effect on CEBL occurrence and increased radiosensitivity of the cerebral periventricular region (VP_4mm). This work aimed to design a stable risk-minimizing treatment planning (TP) concept addressing these intertwined risk factors through a classically formulated optimization problem.</div></div><div><h3>Material and methods</h3><div>The concept was developed in RayStation-research 11B IonPG featuring a variable-RBE-based optimizer involving 20 LGG patients with varying target volume localizations and risk-factor contributions. Classical cost functions penalizing dose, dose-volume-histogram points, and equivalent uniform dose were used to formulate the optimization problem, and a new set of structures was introduced to actively spare the VP_4mm, control high LET_d regions, and de-escalate the dose outside the gross tumor volume. Target volume coverage and organ-at-risk sparing were robustly evaluated, and Normal Tissue Complication Probabilities (NTCP) for CEBL occurrence were quantified.</div></div><div><h3>Results</h3><div>The concept yielded stable optimization outcomes for all considered subjects. Risk hot spots were successfully mitigated, and an NTCP reduction of up to 79 % was observed compared to conventional TP while maintaining target coverage, demonstrating the feasibility of the chosen model-based approach.</div></div><div><h3>Conclusion</h3><div>With the proposed TP protocol, we close the gap between predictive risk-modeling and practical risk-mitigation in the clinic and provide a concept for CEBL avoidance with the potential to advance treatment precision for LGG patients.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110579"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guiding induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma with ternary classification of predicted individual treatment effect","authors":"Zhiying Liang ,&nbsp;Chao Luo ,&nbsp;Shuqi Li ,&nbsp;Yuliang Zhu ,&nbsp;Wenjie Huang ,&nbsp;Di Cao ,&nbsp;Yifei Liu ,&nbsp;Guangying Ruan ,&nbsp;Shaobo Liang ,&nbsp;Xi Chen ,&nbsp;Kit-Ian Kou ,&nbsp;Guoyi Zhang ,&nbsp;Lizhi Liu ,&nbsp;Haojiang Li","doi":"10.1016/j.radonc.2024.110571","DOIUrl":"10.1016/j.radonc.2024.110571","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Induction chemotherapy (IC) before concurrent chemoradiotherapy does not universally improve long-term overall survival (OS) in locoregionally advanced nasopharyngeal carcinoma (LANPC). Conventional risk stratification often yields suboptimal IC decisions. Our study introduces a ternary classification of predicted individual treatment effect (PITE) to guide personalized IC decisions.</div></div><div><h3>Materials and methods</h3><div>A two-center retrospective analysis of 1,213 patients with LANPC was conducted to develop and validate prognostic models integrating magnetic resonance imaging and clinical data to estimate individual 5-year OS probabilities for IC and non-IC treatments. Differences in these probabilities defined PITE, facilitating patient stratification into three IC recommendation categories. Model effectiveness was validated using Kaplan–Meier estimators, decision curve-like analysis, and evaluations of variable importance and distribution.</div></div><div><h3>Results</h3><div>The models exhibited strong predictive performance in both treatments across training and cross-validation sets, enabling accurate PITE calculations and patient classification. Compared with non-IC treatment, IC markedly improved OS in the IC-preferred group (HR = 0.62, p = 0.02), had no effect in the IC-neutral group (HR = 1.00, p = 0.70), and worsened OS in the IC-opposed group (HR = 2.00, p = 0.03). The ternary PITE classification effectively identified 41.7 % of high-risk patients not benefiting from IC, and yielded a 2.68 % higher mean 5-year OS probability over risk-based decisions. Significantly increasing distributions of key prognostic indicators, such as metastatic lymph node number and plasma Epstein–Barr virus DNA level from IC-opposed to IC-preferred groups, further validated the clinical relevance of PITE classification.</div></div><div><h3>Conclusion</h3><div>The ternary PITE classification offers an accurate and clinically advantageous approach to guide personalized IC decision-making in patients with LANPC.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110571"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review of the impact of abdominal compression and breath-hold techniques on motion, inter-fraction set-up errors, and intra-fraction errors in patients with hepatobiliary and pancreatic malignancies","authors":"Amanda Webster ,&nbsp;Yemurai Mundora ,&nbsp;Catharine H. Clark ,&nbsp;Maria A. Hawkins","doi":"10.1016/j.radonc.2024.110581","DOIUrl":"10.1016/j.radonc.2024.110581","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Reducing motion is vital when radiotherapy is used to treat patients with hepatobiliary (HPB) and pancreatic malignancies. Abdominal compression (AC) and breath-hold (BH) techniques aim to minimise respiratory motion, yet their adoption remains limited, and practices vary. This review examines the impact of AC and BH on motion, set-up errors, and patient tolerability in HPB and pancreatic patients.</div></div><div><h3>Materials and methods</h3><div>This systematic review, conducted using PRISMA and PICOS criteria, includes publications from January 2015 to February 2023. Eligible studies focused on AC and BH interventions in adults with HPB and pancreatic malignancies. Endpoints examined motion, set-up errors, intra-fraction errors, and patient tolerability. Due to study heterogeneity, Synthesis Without Meta-Analysis was used, and a 5 mm threshold assessed the impact of motion mitigation.</div></div><div><h3>Results</h3><div>In forty studies, 14 explored AC and 26 BH, with 20 on HPB, 13 on pancreatic, and 7 on mixed cohorts. Six studied pre-treatment, 22 inter/intra-fraction errors, and 12 both. Six AC pre-treatment studies showed &gt; 5 mm motion, and 4 BH and 2 AC studies reported &gt; 5 mm inter-fraction errors. Compression studies commonly investigated the arch and belt, and DIBH was the predominant BH technique. No studies compared AC and BH. There was variation in the techniques, and several studies did not follow standardised error reporting. Patient experience and tolerability were under-reported.</div></div><div><h3>Conclusion</h3><div>The results indicate that AC effectively reduces motion, but its effectiveness may vary between patients. BH can immobilise motion; however, it can be inconsistent between fractions. The review underscores the need for larger, standardised studies and emphasizes the importance of considering the patient’s perspective for tailored treatments.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110581"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on the article by Fleischmann et al. on treatment for recurrent glioma","authors":"Mustafa Mert Hanilce,&nbsp;Cemal Ugur Dursun,&nbsp;Beyhan Ceylaner Bicakci","doi":"10.1016/j.radonc.2024.110564","DOIUrl":"10.1016/j.radonc.2024.110564","url":null,"abstract":"","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110564"},"PeriodicalIF":4.9,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}